Major Fund Manager Acquires Significant Stake in Ocugen Amid Share Price Weakness

A notable divergence is emerging in the Ocugen investment thesis. While the biotech company's shares face persistent technical selling pressure, a substantial regulatory filing reveals a major institutional investor is building a position, viewing the downturn as an entry opportunity.

In a Form 13G filing with the U.S. Securities and Exchange Commission (SEC) dated December 8, asset management firm Janus Henderson Group PLC reported acquiring a significant equity interest in Ocugen. The disclosure outlines the following key details:

• Total Shares Acquired: 20,000,000
• Percentage of Outstanding Shares: 6.0%
• Voting Rights: The shares carry full voting rights.

Notably, the position was established with shares priced around $1.20, aligning with the stock's current trading level. This move represents a classic contrarian investment strategy, where a large-scale buyer enters the market during a period of broad pessimism, often interpreted as a long-term confidence signal in the company's fundamentals.

Should investors sell immediately? Or is it worth buying Ocugen?

Technical Chart Picture Remains Challenging

Despite this institutional vote of confidence, Ocugen's stock chart continues to display weakness. The share price has recently broken below key short-term moving averages, and trading volume has expanded on down days. Intraday price action, fluctuating between $1.18 and $1.26, underscores the current high volatility as the market attempts to find an equilibrium between persistent technical selling and new institutional demand.

Key Price Support Level Under Scrutiny

Market observers are now closely watching the $1.15 to $1.20 price zone to see if it will hold as a support level. The SEC filing has abruptly altered the shareholder structure, potentially redefining the stock's near-term risk profile. With Janus Henderson now a major shareholder, Ocugen's equity has gained a potential stabilizing anchor. Whether this presence is sufficient to halt the prevailing technical downtrend, however, is a question that only subsequent trading sessions will answer.